Evidence of better OS in metastatic colorectal cancer, when bevacizumab is continued beyond progression in the presence of diverse types of chemotherapy, reflects the continued involvement of VEGF as mentioned before [45]. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.